ATAI
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
11 of 31
Related slides by other companies
BioNTech
Results
November 2020
phase a safety profile | BioNTech
Valneva
IPO
April 2021
was well tolerated in phase safety profile within the expected range for an inactivated vaccine ans | Valneva
Nuvalent
Investor Presentation
February 2024
the path to patient impact program status first approved a toe pivotal data naive and study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing product mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in for her | Nuvalent
Theravance Biopharma
Investor Conference
November 2022
new study in patients with cypress | Theravance Biopharma
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights